Table 1.
Clinical characteristics of individuals enrolled in the study n (%)
| Clinical characteristics | HCC number | Control number |
| Age at baseline, years | ||
| ≥ 60 | 20 (32.3) | 6 (27.3) |
| < 60 | 42 (67.7) | 16 (72.7) |
| Median | 55 | 51 |
| Range | 29-76 | 20-72 |
| Sex | ||
| Male | 53 (85.5) | 11 (50.0) |
| Female | 9 (14.5) | 11 (50.0) |
| KPS score | ||
| > 80 | 31 (50.0) | 22 (100.0) |
| 60-80 | 31 (50.0) | 0 (0.0) |
| Hepatitis infection | ||
| HBV positive | 59 (95.2) | 7 (31.2) |
| HBV negative | 3 (4.8) | 15 (68.2) |
| Tumor size (cm) | NA | |
| ≤ 3.0 | 21 (33.9) | |
| > 3.0 | 41 (66.1) | |
| Primary foci | NA | |
| Single | 54 (87.1) | |
| Multiple | 8 (12.9) | |
| Carcinoma cell embolus | NA | |
| Yes | 1 (1.6) | |
| No | 61 (98.4) | |
| AJCC stage at enrollment | NA | |
| Early (stage 1 + 2) | 55 (88.7) | |
| Late (stage 3 + 4) | 7 (11.3) |
HCC: Hepatocellular carcinoma; KPS: Karnofsky performance status; HBV: Hepatitis B virus; AJCC: American Joint Committee on Cancer; NA: Not applicable.